Combination of an IL-1/18 inhibitor with a TNF inhibitor for the treatment of inflammation
AssigneePfizer Inc.
InventorsChristopher A. Gabel, Mark A. Dombroski
Life of this patent
Estimating the term…
Abstract
The invention relates to compositions and methods for treating or preventing inflammation, including rheumatoid arthritis (RA). The method comprises administering to mammals in need thereof an effective amount of a composition containing an agent that inhibits IL-1/18 combination with a TNF inhibitor.
Claims36
A composition for treating inflammation comprising an amount of an IL-1 inhibitor in combination with an amount of a Tumor Necrosis Factor (TNF) inhibitor, wherein the amount of the two components is effective for treating inflammation and a pharmaceutically acceptable carrier.
A composition for treating inflammation comprising an amount of an IL-1 and an IL-18 inhibitor in combination with an amount of a Tumor Necrosis Factor (TNF) inhibitor, wherein the amount of the two components is effective for treating inflammation and a pharmaceutically acceptable carrier.
A method of treating inflammation comprising administering to a mammal in need thereof an amount of an IL-1 inhibitor in combination with an amount of a Tumor Necrosis Factor (TNF) inhibitor, wherein the amount of the two components is effective for treating inflammation.
A method of treating inflammation comprising administering to a mammal in need thereof an amount of an IL-1 inhibitor and an IL-18 inhibitor in combination with an amount of a Tumor Necrosis Factor (TNF) inhibitor, wherein the amount of the two components is effective for treating inflammation.
Dependencies are inferred from the claim text.